Focus on pancreas cancer

Cancer Cell

Volumn 2, Issue 1, 2002, Pages 25-28

  Jaffee, Elizabeth M ^a,c   Hruban, Ralph H ^a,b   Canto, Marcia ^a,b   Kern, Scott E ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN; INDOMETACIN FARNESIL; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P16; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER RESEARCH; CANCER SCREENING; CANCER THERAPY; CELL MEMBRANE; CLINICAL TRIAL; DRUG SAFETY; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; EXPERIMENTAL THERAPY; FORECASTING; GENETICS; PANCREAS TUMOR;

FORECASTING; HUMANS; PANCREATIC NEOPLASMS; THERAPIES, INVESTIGATIONAL;

EID: 0036654827     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00093-4     Document Type: Review

References (27)

1. AGA (American Gastroenterological Association) (1999). American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117, 1463-1484.
2. Argani, P., Iacobuzio-Donahue, C.A., Ryu, R., Goggins, M., Rosty, C., Wilentz, R.E., Murugesan, S., Kaushal, M., Leach, S.D., Jaffee, E.M., et al. (2001a). Mesothelin is expressed in the vast majority of adenocarcinomas of the pancreas: identification of a new cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7, 3862-3868.
3. Argani, P., Rosty, C., Reiter, R.E., Wilentz, R.E., Murugesan, S., Leach, S.B., Ryu, B., Goggins, M., Yeo, C.J., Cameron, J.L., et al. (2001b). Discovery of new markers of cancer through serial analysis of gene expression (SAGE): prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61, 4320-4324.
4. Brentnall, T.A., Bronner, M.P., Byrd, D.R., Haggitt, R.C., and Kimmey, M.B. (1999). Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131, 247-255.
5. Canto, M., Wroblewski, L., Goggins, M., Brun, K., Peterson, G., Giardello, F., Yeo, C., and Hruban, R. (2002). Screening for pancreatic neoplasia in high-risk individuals: the Johns Hopkins experience. Gastroenterology 122 (Suppl. 1), A17.
6. Coughlin, S.S., Calle, E.E., Patel, A.V., and Thun, M.J. (2000). Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11, 915-923.
7. Emens, L.A., Machiels, J.-P., Reilly, R.T., and Jaffee, E.M. (2001). Chemotherapy: friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 3, 77-84.
8. Ghadirian, P., Liu, G., Gallinger, S., Schmocker, B., Paradis, A.J., Lal, G., Brunet, J.S., Foulkes, W.D., and Narod, S.A. (2002). Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int. J. Cancer 97, 807-810.
9. Giardiello, F.M., Brensinger, J., Tersmette, A.C., Goodman, S.N., Petersen, G.M., Booker, S.V., Cruz-Correa, M., and Offerhaus, J.A. (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447-1453.
10. Goggins, M., Schutte, M., Lu, J., Moskaluk, C.A., Weinstein, C.L., Petersen, G.M., Yeo, C.J., Jackson, C.E., Lynch, H.T., Hruban, R.H., and Kern, S.E. (1996). Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360-5364.
11. Goggins, M., Offerhaus, G.J.A., Hilgers, W., Griffin, C.A., Shekher, M., Tang, D., Sohn, T., Yeo, C.J., Kern, S.E., and Hruban, R.H. (1998). Adenocarcinomas of the pancreas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am. J. Pathol. 152, 1501-1507.
12. Goggins, M., Canto, M., and Hruban, R. (2000). Can we screen high-risk individuals to detect early pancreatic carcinoma? J. Surg. Oncol. 74, 243-248.
13. Grimm, H., Maydeo, A., and Soehendra, N. (1990). Endoluminal ultrasound for the diagnosis and staging of pancreatic cancer. Baillieres Clin. Gastroenterol. 4, 869-888.
14. Hao, D., and Rowinsky, E.K. (2002). Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Invest. 20, 387-404.
15. Hilgers, W., and Kern, S.E. (1999). Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 26, 1-12.
16. Hruban, R.H., Wilentz, R., and Kern, S.E. (2000). Genetic progression in the pancreatic ducts. Am. J. Pathol. 156, 1821-1825.
17. Iacobuzio-Donahue, C.A., Ryu, B., Hruban, R.H., and Kern, S.E. (2002). Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am. J. Pathol. 160, 91-99.
18. Jaffee, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann, M., Coleman, J., Grochow, L., Donehower, R.C., et al. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156.
19. Laheru, D., Biedrzycki, B., and Jaffee, E.M. (2001). Immunologic approaches to the management of pancreatic cancer. Cancer J. 7, 324-337.
20. Lowenfels, A.B., Maisonneuve, E.P., Dimagno, Y.E., Gates, L.K., Perrault, J., and Whitcomb, D.C. (1997). International hereditary pancreatitis study group, hereditary pancreatitis and the risk of pancreatic cancer. J. Natl. Cancer Inst. 89, 442-446.
21. Lynch, H.T., Brand, R.E., Hogg, D., Deters, C.A., Fusaro, R.M., Lynch, J.F., Liu, L., Knezetic, J., Lassam, N.J., Goggins, M., et al. (2002). Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94, 84-96.
22. Nakaizumi, A., Uehara, H., Iishi, H., Tatsuta, M., Kitamura, T., Kuroda, C., Ohigashi, H., Ishikawa, O., and Okuda, S. (1995). Endoscopic ultrasonography in diagnosis and staging of pancreatic cancer. Dig. Dis. Sci. 40, 696-700.
23. Rosenberg, L. (2000). Pancreatic cancer. A review of emerging therapies. Drugs 59, 1071-1089.
24. Schwarte-Waldhoff, I., Volpert, O.V., and Bouck, N.P. (2000). SMAD4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. USA 97, 9624-9629.
25. Tersmette, A.C., Petersen, G.M., Offerhaus, G.J.A., Falatko, F.C., Goggins, M., Rosenblum, E., Wilentz, R.E., Yeo, C.J., Cameron, J.L., Kern, S.E., et al. (2001). Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin. Cancer Res. 7, 738-744.
26. Wilentz, R.E., Goggins, M., Redston, M., Marcus, V.A., Adsay, N.V., Sohn, T.A., Kadkol, S.S., Yeo, C.J., Choti, M., Zahurak, M., et al. (2000). Genetic immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity. Am. J. Pathol. 156, 1641-1651.
27. Yamamoto, H., Itoh, F., Nakamura, H., Fukushima, H., Sasaki, S., Perucho, M., and Imai, K. (2001). Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 61, 3139-3144.